ITASCA, IL--(Marketwire - October 13, 2008) - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness non-invasively, today announced that it has signed a new agreement to supply SphygmoCor® systems and clinical trial support services to a leading international pharmaceutical company. The minimum total value of this contract is US$930,000, the majority of which will be recognized in the current financial year. This new order brings the minimum total value of pharmaceutical trial contracts secured by AtCor in the past 130 days to over US $3.7 million.
